EMA/38355/2017

European Medicines Agency decision

P/0035/2017

of 31 January 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vadadustat (EMEA-001944-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

An agency of the European Union

European Medicines Agency decision

P/0035/2017

of 31 January 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for vadadustat (EMEA-001944-PIP01-16) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Akebia Therapeutics, Inc. on 21 March 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 December 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for vadadustat, tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for vadadustat, tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for vadadustat, tablet, age-appropriate oral formulation, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Akebia Therapeutics, Inc., 245 First Street, Suite 1100, 02142 - Cambridge, MA, United States.

EMA/PDCO/655705/2016
London, 16 December 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMEA-001944-PIP01-16

Scope of the application

Active substance(s):

Vadadustat

Condition(s):

Treatment of anaemia due to chronic disorders

Pharmaceutical form(s):

Tablet

Age-appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Akebia Therapeutics, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Akebia Therapeutics, Inc. submitted for agreement to the European Medicines Agency on 21 March 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 26 April 2016.

Supplementary information was provided by the applicant on 26 September 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
   - to grant a deferral in accordance with Article 21 of said Regulation;
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of anaemia due to chronic disorders

The waiver applies to:

- the paediatric population from birth to less than 4 months of age;
- tablet and age appropriate oral formulation, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition

Treatment of anaemia due to chronic disorders

2.1.1. Indication(s) targeted by the PIP

Treatment of anaemia secondary to chronic kidney disease

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Age appropriate oral formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate oral dosage form.
Non-clinical studies	2	**Study 2** Dose range-finding study in juvenile dogs. **Study 3** Definitive toxicity study in juvenile dogs.

Clinical studies	4	**Study 4** Open-label, single-arm, externally controlled trial to evaluate the activity, safety, tolerability, PK and PD of oral vadadustat for the correction of anaemia in children from 4 months to less than 18 years of age with anaemia secondary to chronic kidney disease (CKD). **Study 5** Medical record review study to assess the activity and safety of ESA treatment to correct and maintain haemoglobin levels in children from 4 months to less than 18 years of age with anaemia secondary to CKD and naïve to ESA treatment. **Study 6** Open-label, single-arm, externally controlled trial to evaluate the activity, safety, tolerability, PK and PD of oral vadadustat for the maintenance treatment of anaemia in children from 4 months to less than 18 years of age with anaemia secondary to CKD receiving ESA treatment. **Study 7** Medical record review study to assess the activity and safety of ESA treatment to maintain haemoglobin levels in children from 4 months to less than 18 years of age with anaemia secondary to CKD receiving ESA treatment.
Extrapolation, modelling and simulation studies	1	**Study 8** Modelling and simulation study to develop PK/PD simulations for the prediction of exposure and selection of doses to be used in children from 4 months to less than 18 years of age with anaemia secondary to CKD naïve to ESA treatment or receiving ESA treatment.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes